Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
Arvinas, Inc. and Pfizer entered into an agreement with Rigel Pharmaceuticals granting Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant), the first FDA-approved PROTAC drug for certain advanced breast cancers. Arvinas and Pfizer will receive $85 million upfront combined with potential milestones totali…